BiotechTube

Placebo + RO5459072

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Mar 6, 2016 → Aug 28, 2016

NCT ID
NCT02679014

About Placebo + RO5459072

Placebo + RO5459072 is a phase 1 stage product being developed by Roche for Celiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02679014. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02701985Phase 2Completed
NCT02679014Phase 1Completed

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
DONQ52 + PlaceboChugai PharmaceuticalPhase 1
29
Placebo DONQ52 + DONQ52Chugai PharmaceuticalPhase 2
42
CCX282-B + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
Rifaximin + PlaceboBausch HealthPre-clinical
20
LatiglutenaseAllergy TherapeuticsPhase 2
21
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26